OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press5310.17650/1818-8346-2012-7-3-369-374BASIC RESEARCHФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕClinical value of blood circulating (1→3)β-D-glucan in patients with suspected invasive fungal infectionКлиническое значение определения циркулирующего (1→3)-β-D-глюкана в крови пациентов при подозрении на инвазивную грибковую инфекциюPirumovavV. P.ПирумоваВ. П.
Russian Federation
v.pirumova@gmail.comGelfandM. S.ГельфандМ. С.
Russian Federation
Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииHealth Science Center, The University of TennesseeНаучный центр здоровья Университета штата Теннесси2208201273434822072014220720142012https://oncohematology.abvpress.ru/ongm/article/view/53

Invasive fungal infections (IFI) are a heterogeneous group of diseases, whose clinical significance is increased due to large number of cancerpatients, patients with aplastic anemia, congenital or acquired immunity defects. Morbidity and mortality due to fungal infection remain high, and the available diagnostic methods do not always allow timely detect and isolate infection pathogen. Microbiological and histological examination of biopsy material is the “gold standard” of IFI diagnostic, but in practice it is often associated with high risk for patients. Reliable nonculture methods of early IFI detection needed to improve current diagnostic and allowing an earlier decision of specific antifungal therapy. This article presents the advantages and limitations of one of these tests. In recent years, many articles and reviews about circulating (1→3)β-D-glucan (BDG) detection (major cell wall component of most pathogenic fungi) has appeared in the available literature. Despite that this test has a high diagnostic value, to recommend it for routine use in children with febrile neutropenia is premature. This test is less useful in making timely decision about diagnosis and start of antifungal therapy because of moderate sensitivity and specificity, the lack of evaluation criteria in children, late results (if detected in reference laboratory) and cost. BDG detection results can be interpreted only in conjunction with clinical course and data of routine laboratory and radiological methods.

invasive fungal infectioncirculating (1→3)β-D-glucanbeta-glucan testинвазивные грибковые инфекциициркулирующий (1→3)-β-D-глюканбета-глюкан тест1. Масчан А.А., Клясова Г.А., Веселов А.В. Обзор рекомендаций Американского общества по инфекционным болезням по лечению аспергиллеза. Клин микробиол и антимикроб химиотер 2008;10(2):96−143.Масчан А.А., Клясова Г.А., Веселов А.В. Обзор рекомендаций Американского общества по инфекционным болезням по лечению аспергиллеза. Клин микробиол и антимикроб химиотер 2008;10(2):96−143.2. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. М.: Медпрактика-М, 2006.Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. М.: Медпрактика-М, 2006.3. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 1997;90:999−1008.Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 1997;90:999−1008.4. Girmenia C., Nucci M., Martino P. Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. Br J Hematol 2001;114(1):93−8.Girmenia C., Nucci M., Martino P. Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. Br J Hematol 2001;114(1):93−8.5. Hachem R.Y., Kontoyiannis D.P., Chemaly R.F. et al. Utility of galactomannan enzyme immunoassay and (11-->33)-b-Dglucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009;47:129−33.Hachem R.Y., Kontoyiannis D.P., Chemaly R.F. et al. Utility of galactomannan enzyme immunoassay and (11-->33)-b-Dglucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009;47:129−33.6. Hope W.W., Walsh T.J., Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609−22. 7. Hossain M.A., Miyazaki T., Mitsutake K. Comparison between Wako-WB003 and Fungitec G tests for detection of (1-->3)-β-d-glucan in systemic mycosis. J Clin Lab Anal 1997;11:73−7.Hope W.W., Walsh T.J., Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609−22. 7. Hossain M.A., Miyazaki T., Mitsutake K. Comparison between Wako-WB003 and Fungitec G tests for detection of (1-->3)-β-d-glucan in systemic mycosis. J Clin Lab Anal 1997;11:73−7.8. Karageorgopoulos D.E., Vouloumanou E.K., Ntziora F. et al. β-d- Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52(6):750−77.Karageorgopoulos D.E., Vouloumanou E.K., Ntziora F. et al. β-d- Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52(6):750−77.9. Kato A., Takita T., Furuhashi M. Elevation of blood (103)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001;89:15−9.Kato A., Takita T., Furuhashi M. Elevation of blood (103)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001;89:15−9.10. Kawagishi N., Miyagi S., Satoh K. et al. Usefulness of beta-D glucan in diagnosing Pneumocystis cariniipneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007;14:308−11.Kawagishi N., Miyagi S., Satoh K. et al. Usefulness of beta-D glucan in diagnosing Pneumocystis cariniipneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007;14:308−11.11. Kedzierska A., Kochan P., Pietrzyk A. et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: Galactomannan, mannan and (1-3)-β-Dglucan antigens. Eur J Clin Microbiol Infect Dis 2007;26:755−66.Kedzierska A., Kochan P., Pietrzyk A. et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: Galactomannan, mannan and (1-3)-β-Dglucan antigens. Eur J Clin Microbiol Infect Dis 2007;26:755−66.12. Kimura Y., Nakao A., Tamura H. et al. Clinical and experimental studies of the Limulus test after digestive surgery. Surg Today 1995;25:790−4.Kimura Y., Nakao A., Tamura H. et al. Clinical and experimental studies of the Limulus test after digestive surgery. Surg Today 1995;25:790−4.13. Lamoth F., Cruciani M., Mengoli C. et al. Beta-glucanantigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European conference on infections in leukemia (ECIL-3). Clinical Infect Dis 2012; 54(5):633−43.Lamoth F., Cruciani M., Mengoli C. et al. Beta-glucanantigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the third European conference on infections in leukemia (ECIL-3). Clinical Infect Dis 2012; 54(5):633−43.14. Marchetti O., Lamoth F., Mikulska M. et al. ECIL recommendations for the use of biological arkers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. BMT 2012;47:846−54.Marchetti O., Lamoth F., Mikulska M. et al. ECIL recommendations for the use of biological arkers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. BMT 2012;47:846−54.15. Marty F.M., Koo S. Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47(suppl 1):233−40.Marty F.M., Koo S. Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47(suppl 1):233−40.16. Marty F.M., Lowry C.M., Lempitski S.J. et al. Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006;50:3450−3.Marty F.M., Lowry C.M., Lempitski S.J. et al. Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006;50:3450−3.17. Mennik-Karsten M.A., Ruegebrink D., Verwei P.E. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008;46:1930−1.Mennik-Karsten M.A., Ruegebrink D., Verwei P.E. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008;46:1930−1.18. Miyazaki T., Kohno S., Mitsutake K. et al. Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995;33:3115−8.Miyazaki T., Kohno S., Mitsutake K. et al. Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995;33:3115−8.19. Mohr J., Paetznick V.L., Rodriguez J.R. et al. A prospective pilot survey of B-glucan (BG) seropositivity and its relationship to invasive candidiasis (IC) in the surgical ICU (SICU) (Abstract M-168). 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy, 2005; Washington, DC.Mohr J., Paetznick V.L., Rodriguez J.R. et al. A prospective pilot survey of B-glucan (BG) seropositivity and its relationship to invasive candidiasis (IC) in the surgical ICU (SICU) (Abstract M-168). 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy, 2005; Washington, DC.20. Mularoni A., Furfaro E., Faraci M. et al. High levels of b-D-Glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol 2010; 17(5):882−3.Mularoni A., Furfaro E., Faraci M. et al. High levels of b-D-Glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol 2010; 17(5):882−3.21. Obayashi T., Yoshida M., Mori T. et al. Plasma (1-->3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345:17−20.Obayashi T., Yoshida M., Mori T. et al. Plasma (1-->3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345:17−20.22. Odabasi Z., Mattiuzzi G., Estey E. et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199−205.Odabasi Z., Mattiuzzi G., Estey E. et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199−205.23. Ostrosky-Zeichner L., Alexander B.D., Kett D.H. et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654−9.Ostrosky-Zeichner L., Alexander B.D., Kett D.H. et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654−9.24. Pazos C., Pontón J., Del Palacio A. Contribution of (1-->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005;43:299−305.Pazos C., Pontón J., Del Palacio A. Contribution of (1-->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005;43:299−305.25. Person A.K., Kontoyiannis D.P., Alexander B.D. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24:439−59.Person A.K., Kontoyiannis D.P., Alexander B.D. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24:439−59.26. Pickering J.W., Sant H.W., Bowles C.A. et al. Evaluation of a (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43:5957−62.Pickering J.W., Sant H.W., Bowles C.A. et al. Evaluation of a (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43:5957−62.27. Segal B.H., Almyroudis N.G., Battiwalla M. et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402−9.Segal B.H., Almyroudis N.G., Battiwalla M. et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402−9.28. Smith P.B., Benjamin D.K. Jr, Alexander B.D. et al. Quantification of 1,3-beta-d-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 2007;14(7):924−5.Smith P.B., Benjamin D.K. Jr, Alexander B.D. et al. Quantification of 1,3-beta-d-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol 2007;14(7):924−5.29. Verweij P.E., Figueroa J., Van Burik J. et al. Clinical applications of nonculture based methods for the diagnosis and management of opportunistic and endemic mycoses. Med Mycol 2000;38:161−71.Verweij P.E., Figueroa J., Van Burik J. et al. Clinical applications of nonculture based methods for the diagnosis and management of opportunistic and endemic mycoses. Med Mycol 2000;38:161−71.30. Wright W.F., Overman S.B., Ribes J.A. (1−3)-β-D-Glucan assay: a review of its laboratory and clinical application. Lab Med 2011;42(11):679−85.Wright W.F., Overman S.B., Ribes J.A. (1−3)-β-D-Glucan assay: a review of its laboratory and clinical application. Lab Med 2011;42(11):679−85.